Scancell Holdings plc

LSE SCLP.L

Scancell Holdings plc Gross Profit for the year ending April 30, 2024: USD -1.21 M

Scancell Holdings plc Gross Profit is USD -1.21 M for the year ending April 30, 2024, a -120.24% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Scancell Holdings plc Gross Profit for the year ending April 30, 2023 was USD 5.96 M, a 741.19% change year over year.
Scancell Holdings plc Gross Profit for the year ending April 30, 2022 was USD -930.02 K, a -170.35% change year over year.
Scancell Holdings plc Gross Profit for the year ending April 30, 2021 was USD -344.01 K, a -535.41% change year over year.
Scancell Holdings plc Gross Profit for the year ending April 30, 2020 was USD -54.14 K, a -97.27% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

LSE: SCLP.L

Scancell Holdings plc

CEO	Dr. Phillip John L'Huillier
IPO Date	Feb. 12, 2010
Location	United Kingdom
Headquarters	Unit 202 Bellhouse Building
Employees	61
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Key trends

Past 5 years